MRVI Maravai LifeSciences Holdings

Maravai LifeSciences Strengthens Executive Leadership Team to Support Long-Term Growth

Maravai LifeSciences Strengthens Executive Leadership Team to Support Long-Term Growth

Appointment of Dr. Peter Leddy as Executive Vice President and Chief Administrative Officer

SAN DIEGO, June 27, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced today that Peter Leddy, Ph.D. (“Pete”) has joined the Company as Executive Vice President and Chief Administrative Officer.

In this newly created role, Pete will have responsibility for leading Maravai’s global shared services functions, including Human Resources, Environmental, Social and Governance initiatives, Diversity Equity and Inclusion initiatives, Global Facilities, and Security.  

“We are very pleased to welcome Pete to the Maravai senior leadership team,” said Carl Hull. “His extensive experience in the healthcare sector brings valuable insights as we scale the organization for expected, continued long-term growth. Pete has a proven track record of developing and implementing strategies to enhance growth and attract and retain talent while strengthening company culture, and I expect him to play an incredibly important cross-functional role across the organization. He will work in close partnership with me on the execution of key strategic initiatives and the management of key performance indicators."

Pete has over 30 years of experience leading growth and change across a wide variety of businesses, and specifically in scaling global healthcare companies. Throughout 2022, Pete has worked as a consultant to Maravai on a number of issues related to organizational design, compensation and retention. Previously, Pete served as Chief Human Resources Officer at Berkeley Lights, Chief People Officer at dosist, Executive Vice President, Global Human Resources and Corporate Integrity at Nuvasive and Chief Human Resources Officer at Life Technologies and Invitrogen. Earlier in his career he held a variety of executive and human resource positions at Dell, Promus Hotel Corp. and PepsiCo. He received his B.A. in Psychology from Creighton University and his M.S. and Ph.D. degrees in industrial/organizational psychology from the Illinois Institute of Technology.  

Pete Leddy commented, "Maravai is at a tremendous inflection point in its journey, and I’m excited to join a company with a strong, high-performance culture, grounded in humility and focused on improving human health. I look forward to bringing my knowledge and leadership to this important new role and furthering the Company’s success."

About Maravai

Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.

Forward-looking Statements

This press release may contain "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release which are not strictly historical statements constitute forward-looking statements, including, without limitation, statements related to our expectations for continued long-term growth and further success, constitute forward-looking statements identified by words like “will,” “expect,” “may,” “anticipate,” or “could” and similar expressions. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including continued demand for our COVID-19 related products and services, which currently comprise a significant portion of our revenue. These and other risks and uncertainties are described in greater detail in the “Risk Factors” section of our most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission. Actual results may differ materially from those contemplated by these forward-looking statements, and therefore you should not rely upon them. These forward-looking statements reflect our current views and we do not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date hereof except as required by law.





Media Contact: Sara Michelmore
MacDougall
 
  

Investor Contact: Deb Hart
Maravai LifeSciences
 7
 
EN
27/06/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Maravai LifeSciences Holdings

 PRESS RELEASE

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Offic...

Maravai LifeSciences Appoints Rajesh Asarpota as Chief Financial Officer SAN DIEGO, June 25, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced that Rajesh “Raj” Asarpota has been appointed Executive Vice President (EVP) and Chief Financial Officer (CFO), effective June 30, 2025. He will succeed Kevin Herde, who is transitioning to an advisory role on the same date to support an effective transition.  “We thank Kevin for his commitment to Maravai and his...

 PRESS RELEASE

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer a...

Maravai LifeSciences Appoints Bernd Brust as Chief Executive Officer and Member of its Board of Directors SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the appointment of Bernd Brust as Chief Executive Officer (CEO) and a member of the Board of Directors, effective immediately. Mr. Brust succeeds William “Trey” Martin III in these roles. “This leadership transition reflects Maravai’s commitment to accelerating innovation, execut...

 PRESS RELEASE

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report

CORRECTION – Maravai LifeSciences Releases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- This release corrects and replaces the version distributed earlier today at 16:05 ET. The original version included the ...

 PRESS RELEASE

Maravai LifeSciencesReleases 2024 Sustainability Report

Maravai LifeSciencesReleases 2024 Sustainability Report Accelerates product innovation, expands GMP manufacturing capacity, and deepens corporate-wide commitment to responsible growth Debuts enhanced greenhouse gas accounting across Scopes 1-3 and advances renewable energy initiatives Strengthens governance with appointment of independent Chairman of the Board and launches site level ethics liaison program SAN DIEGO, May 21, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of lifescience reagents and services to researchers and biotech ...

 PRESS RELEASE

Maravai Lifesciences Reports First Quarter 2025 Financial Results

Maravai Lifesciences Reports First Quarter 2025 Financial Results SAN DIEGO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today reported financial results for the first quarter ended March 31, 2025, together with other business updates. Financial Highlights: Quarterly revenue of $46.9 million, Net loss of $(52.9) million (including a goodwill impairment of $12.4 million), and Adjusted EBITDA of $(10.5) million; andRevenue for the full y...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch